Sonoma Pharmaceuticals (SNOA) Other Non-Current Assets (2011 - 2026)
Sonoma Pharmaceuticals (SNOA) posted quarterly Other Non-Current Assets of $64000.0 for Q1 2026, down 13.51% year-over-year from $74000.0 in Q1 2025, and little changed quarter-over-quarter from $64000.0 in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Other Non-Current Assets (2011 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Other Non-Current Assets history runs 16 years deep, the most recent figure standing at $64000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 13.51% year-over-year to $64000.0; the TTM figure through Mar 2026 stood at $64000.0 (down 13.51% YoY), while the FY2026 annual figure was $64000.0, down 13.51% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $64000.0, roughly flat from $64000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $308000.0 in Q4 2022, with the low at $61000.0 in Q2 2024.
- The 5-year median for Other Non-Current Assets is $76000.0 (2024), against an average of $98823.5.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets soared 310.67% in 2022, then tumbled 74.68% in 2023.
- Sonoma Pharmaceuticals' Other Non-Current Assets stood at $308000.0 in 2022, then sank by 74.68% to $78000.0 in 2023, then decreased by 6.41% to $73000.0 in 2024, then slipped by 12.33% to $64000.0 in 2025, then changed by 0.0% to $64000.0 in 2026.
- Business Quant data shows SNOA's Other Non-Current Assets at $64000.0 in Q1 2026, $64000.0 in Q4 2025, and $84000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | 13.00 Mn |
| 10 | Sonoma Pharmaceuticals | 5.17 Mn | -165,129.89 | 2.58 Mn | 66,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 66,000.00 |
| Mar 31, 2026 | 64,000.00 |
| Dec 31, 2025 | 64,000.00 |
| Sep 30, 2025 | 84,000.00 |
| Jun 30, 2025 | 80,000.00 |
| Mar 31, 2025 | 74,000.00 |
| Dec 31, 2024 | 73,000.00 |
| Sep 30, 2024 | 76,000.00 |
| Jun 30, 2024 | 61,000.00 |
| Mar 31, 2024 | 66,000.00 |
| Dec 31, 2023 | 78,000.00 |
| Sep 30, 2023 | 75,000.00 |
| Jun 30, 2023 | 77,000.00 |
| Mar 31, 2023 | 73,000.00 |
| Dec 31, 2022 | 308,000.00 |
| Sep 30, 2022 | 238,000.00 |
| Jun 30, 2022 | 112,000.00 |
| Mar 31, 2022 | 77,000.00 |
| Dec 31, 2021 | 75,000.00 |
| Sep 30, 2021 | 76,000.00 |